Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cells (VA Office of Research and Development)
- Development stage
- Unknown
- Lead developer
- VA Office of Research & Development
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell-based therapy consists of allogenic bone marrow-derived mesenchymal stem cells (MSCs) being developed by the VA Office of Research and Development for the treatment of age-related frailty in Veterans. Mesenchymal stem cells are multipotent, undifferentiated cells capable of self-renewal and differentiation into various cell lineages. The therapeutic approach utilizes the ability of MSCs to home to sites of tissue injury and inflammation in response to signaling from damaged cells. Once localized, the MSCs exert their effects through paracrine signaling, releasing a variety of growth factors and immune modulators that promote tissue repair, reduce systemic inflammation, and address the stem cell depletion associated with the aging process. The therapy is currently being evaluated in a Phase 1/2 pilot trial to assess its safety, feasibility, and efficacy in improving functional independence in older Veterans.
- Other names
- Allogenic bone marrow-derived mesenchymal stem cellsMSCsMesenchymal Stem Cells
Beyond the preview
Go deeper on mesenchymal stem cells (VA Office of Research and Development).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cells (VA Office of Research and Development).